NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$22.18

+0.34 (+1.56%)

(As of 01/27/2023 11:36 AM ET)

Add

Compare

Today's Range: $21.68
▼
$22.55
50-Day Range: $18.67
▼
$23.62
52-Week Range: $8.85
▼
$24.33

Volume: 825,462 shs
Average Volume: 1.63 million shs
Market Capitalization: $2.68 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.20

Institutional Ownership

IVERIC bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 18.1% Upside
$26.20 Price Target
Short Interest: Bearish
9.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.91
Based on 7 Articles This Week
Insider Trading: Selling Shares
$4.55 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.43) to ($1.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

Medical Sector

1010th out of 1,055 stocks

Pharmaceutical Preparations Industry

493rd out of 519 stocks

2.4

Analyst's Opinion

Consensus Rating
IVERIC bio has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.20, IVERIC bio has a forecasted upside of 18.1% from its current price of $22.18.
Amount of Analyst Coverage
IVERIC bio has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.36% of the outstanding shares of IVERIC bio have been sold short.
Short Interest Ratio / Days to Cover
IVERIC bio has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in IVERIC bio has recently increased by 3.39%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
IVERIC bio does not currently pay a dividend.
Dividend Growth
IVERIC bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ISEE.

3.3

News and Social Media Coverage

News Sentiment
IVERIC bio has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for IVERIC bio this week, compared to 2 articles on an average week.
Search Interest
11 people have searched for ISEE on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added IVERIC bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IVERIC bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,545,066.00 in company stock.
Percentage Held by Insiders
Only 2.70% of the stock of IVERIC bio is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IVERIC bio are expected to decrease in the coming year, from ($1.43) to ($1.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IVERIC bio is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IVERIC bio is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IVERIC bio has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

January 25, 2023 | americanbankingnews.com

IVERIC bio, Inc. (NASDAQ:ISEE) Receives $28.22 Average Price Target from Brokerages

January 24, 2023 | finance.yahoo.com

Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8b

January 27, 2023 | Investing Trends (Ad)

"We need batteries. Literally everywhere."

Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."

January 23, 2023 | americanbankingnews.com

IVERIC bio, Inc. (NASDAQ:ISEE) Sees Significant Increase in Short Interest

January 3, 2023 | finance.yahoo.com

RTP gene therapy startup expands pipeline through deal with public biotech

January 3, 2023 | finance.yahoo.com

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

December 20, 2022 | markets.businessinsider.com

IVERIC Bio Completes Rolling NDA Submission For Avacincaptad Pegol - Quick Facts

December 20, 2022 | finance.yahoo.com

Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

January 27, 2023 | Investing Trends (Ad)

"We need batteries. Literally everywhere."

December 7, 2022 | seekingalpha.com

Iveric bio: Building Momentum Around Zimura, Rate Buy

November 18, 2022 | msn.com

Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket

November 18, 2022 | marketwatch.com

Iveric bio Shares Rally Premarket on FDA Breakthrough Designation >ISEE

November 18, 2022 | finance.yahoo.com

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

November 18, 2022 | finance.yahoo.com

IVERIC bio Secures Breakthrough Therapy Tag For Its Flagship Geographic Atrophy Candidate

November 4, 2022 | finance.yahoo.com

Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

November 4, 2022 | finance.yahoo.com

IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript

November 4, 2022 | finance.yahoo.com

Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio

November 3, 2022 | msn.com

IVERIC bio: Q3 Earnings Insights

November 3, 2022 | finance.yahoo.com

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

November 2, 2022 | msn.com

IVERIC bio's Earnings: A Preview

October 27, 2022 | finance.yahoo.com

Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022

October 5, 2022 | benzinga.com

IVERIC bio Whale Trades For October 05

September 27, 2022 | finance.yahoo.com

Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

September 8, 2022 | finance.yahoo.com

Why Iveric Bio Stock Is Skyrocketing This Week

September 7, 2022 | markets.businessinsider.com

Analyst Ratings for IVERIC bio

September 7, 2022 | finance.yahoo.com

Iveric Bio to Present at Upcoming Investor Conferences

September 6, 2022 | seekingalpha.com

Hot Stocks: Trump SPAC DWAC drops; FRO rallies on upgrade; ISEE jumps on clinical data; SMG sets new 52-week low

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings: 11/03/2022
Today: 1/27/2023
Next Earnings (Estimated): 2/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ISEE
CUSIP: N/A
CIK: 1410939
Web: ivericbio.com
Phone: (609) 474-6755
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $26.20
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +18.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.10%
Return on Assets: -45.69%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 13.40
Quick Ratio: 13.40

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.14 per share
Price / Book: 7.06

Miscellaneous

Outstanding Shares: 120,723,000
Free Float: 117,463,000
Market Cap: $2.68 billion
Optionable: Optionable
Beta: 1.05

Key Executives

Glenn P. Sblendorio
Chief Executive Officer & Director

Pravin U. Dugel
President & Director

Keith Westby
Chief Operating Officer & Senior Vice President

David F. Carroll
Chief Financial Officer, Treasurer & Senior VP

Xiao Ping Dai
Chief Technical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings or view top-rated stocks.
What is IVERIC bio's stock price forecast for 2023?: 9 Wall Street analysts have issued 1 year price objectives for IVERIC bio's shares. Their ISEE share price forecasts range from $8.00 to $35.00. On average, they predict the company's stock price to reach $26.20 in the next year. This suggests a possible upside of 18.1% from the stock's current price.
View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts.
How have ISEE shares performed in 2023?: IVERIC bio's stock was trading at $21.41 at the start of the year. Since then, ISEE stock has increased by 3.6% and is now trading at $22.18.
View the best growth stocks for 2023 here.
When is IVERIC bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ISEE earnings forecast.
How were IVERIC bio's earnings last quarter?: IVERIC bio, Inc. (NASDAQ:ISEE) posted its earnings results on Thursday, November, 3rd. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05.
What is Glenn Spina's approval rating as IVERIC bio's CEO?: 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).
What is IVERIC bio's stock symbol?: IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."
Who are IVERIC bio's major shareholders?: IVERIC bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%), Dupont Capital Management Corp (0.02%), Strs Ohio (0.01%), Rothschild Investment Corp IL (0.01%), Toth Financial Advisory Corp (0.00%) and FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends.
How do I buy shares of IVERIC bio?: Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IVERIC bio's stock price today?: One share of ISEE stock can currently be purchased for approximately $22.18.
How much money does IVERIC bio make?: IVERIC bio (NASDAQ:ISEE) has a market capitalization of $2.68 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.
How can I contact IVERIC bio?: IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IVERIC bio - ISEE Stock Forecast, Price & News

IVERIC bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About IVERIC bio (NASDAQ:ISEE) Stock

ISEE Stock News Headlines

ISEE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ISEE Stock - Frequently Asked Questions

Overall MarketRank^™